 |
 |
searching for information on dopamine agonists took me to some sites regarding diabetes that might be interesting. Ergo Corporation has a version of bromocriptine. http://pslgroup.com/dg/2ce06.htm http://www.pslgroup.com/dg/3160a.htm HELSINKI, FINLAND -- July 22, 1997 -- Researchers report that combination therapy with neurotransmitter modulating drugs, called dopamine D1/D2 agonists, normalizes insulin secretory dysfunction in a diabetic animal model (db/db mouse). The findings were presented this week at the 16th International Diabetes Federation (IDF) Congress in Helsinki. "Impaired insulin secretion is a common abnormality of diabetes, which contributes to the high blood glucose level," stated Anthony H. Cincotta, Ph.D., Chief Scientific Officer and Executive Vice President of Ergo Science. Dr. Cincotta continued, "Improvement in impaired insulin secretion should lead to better glucose control." Additional results presented this week include: 1) information on the mechanism of action for Ergoset in the treatment of Type 2 diabetes, reinforcing the utility of Ergo Science's Neuroendocrine Resetting Therapy for metabolic disorders, and 2) a study demonstrating the potential for Ergo Science's second-generation combination therapy approach, dopamine D1/D2 agonist, in the treatment of Type II diabetes and obesity. Highlights of the additional abstracts presented are as follows: -- Results of a preclinical study demonstrated that serotonergic and noradrenergic activities within the brain are associated with and may promote glucose intolerance. Glucose intolerance or the body's inability to transport blood glucose into the tissues generally arises from an inability to utilize and/or produce insulin. Glucose intolerance is associated with Type II diabetes. -- Results from preclinical animal models of obesity and diabetes (ob/ob and db/db mice) indicate that treatment with dopamine D1/D2 agonists induced metabolic improvements. Data from our laboratories demonstrate that hyperphagia, hyperglycemia and hyperlipidemia in animals either lacking leptin (ob/ob) or a functional leptin receptor (db/db) can be successfully treated with the combined administration of dopamine D1/D2 receptor agonists. "Collectively, these findings demonstrated that dopamine D1/D2 agonist combination therapy may be used for not only improving carbohydrate and lipid metabolism, but also, for normalizing insulin secretion in diabetic animal models," Dr. Cincotta concluded. http://www.ergo.com/research.htm this page was interesting to me. Merry Christmas to all. -- Ron Vetter 1936, '84 PD dz 'paradise is where you make it, not a place to go' janet [log in to unmask] http://www.ridgecrest.ca.us/~rfvetter